Terms: = Brain cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
794 results:
1. Multi-cohort comprehensive analysis unveiling the clinical value and therapeutic effect of
Liu Z; Yang L; Xie Z; Yu H; Gu T; Shi D; Cai N; Zhuo S
Oncol Res; 2024; 32(5):965-981. PubMed ID: 38686055
[TBL] [Abstract] [Full Text] [Related]
2. Adaptive immune changes associate with clinical progression of Alzheimer's disease.
van Olst L; Kamermans A; Halters S; van der Pol SMA; Rodriguez E; Verberk IMW; Verberk SGS; Wessels DWR; Rodriguez-Mogeda C; Verhoeff J; Wouters D; Van den Bossche J; Garcia-Vallejo JJ; Lemstra AW; Witte ME; van der Flier WM; Teunissen CE; de Vries HE
Mol Neurodegener; 2024 Apr; 19(1):38. PubMed ID: 38658964
[TBL] [Abstract] [Full Text] [Related]
3. Inhibition of autophagy-related protein 7 enhances anti-tumor immune response and improves efficacy of immune checkpoint blockade in microsatellite instability colorectal cancer.
Zhang W; Chen L; Liu J; Chen B; Shi H; Chen H; Qi H; Wu Z; Mao X; Wang X; Huang Y; Li J; Yu Z; Zhong M; Wang T; Li Q
J Exp Clin Cancer Res; 2024 Apr; 43(1):114. PubMed ID: 38627815
[TBL] [Abstract] [Full Text] [Related]
4. Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell Lung cancer Treated with pd-1/PD-L1 Inhibitors: A Single Institutional Cohort Study.
Yuan Q; Xu C; Wang W; Zhang Q
Technol Cancer Res Treat; 2024; 23():15330338241246651. PubMed ID: 38613344
[TBL] [Abstract] [Full Text] [Related]
5. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
[TBL] [Abstract] [Full Text] [Related]
6. CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-pd-1 therapy.
Pant A; Hwa-Lin Bergsneider B; Srivastava S; Kim T; Jain A; Bom S; Shah P; Kannapadi N; Patel K; Choi J; Cho KB; Verma R; Yu-Ju Wu C; Brem H; Tyler B; Pardoll DM; Jackson C; Lim M
Oncoimmunology; 2024; 13(1):2338965. PubMed ID: 38590799
[TBL] [Abstract] [Full Text] [Related]
7. Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer.
Divan HA; Bittoni MA; Krishna A; Carbone DP
BMC Cancer; 2024 Apr; 24(1):424. PubMed ID: 38580900
[TBL] [Abstract] [Full Text] [Related]
8. Associations of pd-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract] [Full Text] [Related]
9. REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
Picca A; Touat M; Belin L; Gourmelon C; Harlay V; Cuzzubbo S; Cohen-Jonathan Moyal E; Bronnimann C; Di Stefano AL; Laurent I; Lerond J; Carpentier C; Bielle F; Ducray F; Dehais C;
Eur J Cancer; 2024 May; 202():114034. PubMed ID: 38537315
[TBL] [Abstract] [Full Text] [Related]
10. brain Delivery of Biomimetic Phosphorus Dendrimer/Antibody Nanocomplexes for Enhanced Glioma Immunotherapy via Immune Modulation of T Cells and Natural Killer Cells.
Peng Y; Zhan M; Karpus A; Zou Y; Mignani S; Majoral JP; Shi X; Shen M
ACS Nano; 2024 Apr; 18(14):10142-10155. PubMed ID: 38526307
[TBL] [Abstract] [Full Text] [Related]
11. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
Albrecht LJ; Dimitriou F; Grover P; Hassel JC; Erdmann M; Forschner A; Johnson DB; Váraljai R; Lodde G; Placke JM; Krefting F; Zaremba A; Ugurel S; Roesch A; Schulz C; Berking C; Pöttgen C; Menzies AM; Long GV; Dummer R; Livingstone E; Schadendorf D; Zimmer L
Eur J Cancer; 2024 May; 202():113976. PubMed ID: 38484692
[TBL] [Abstract] [Full Text] [Related]
12. Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung cancer: A Multiregional Chart Review in the United States, Europe, and Japan.
Leal TA; Dasgupta A; Latremouille-Viau D; Rossi C; Rai P; Barlesi F; Liu SV
JCO Glob Oncol; 2024 Mar; 10():e2300483. PubMed ID: 38484195
[TBL] [Abstract] [Full Text] [Related]
13. [Interest of focal radiotherapy in case of oligoprogression under immunotherapy in the treatment of metastatic non-small cell lung cancer].
Gagé A; Pereira B; Belliere A; Janicot H; Jeannin G; Bourrachot C; Durand M; Rolland-Debord C; Merle P
Bull Cancer; 2023 Dec; 110(12):1234-1243. PubMed ID: 38445648
[TBL] [Abstract] [Full Text] [Related]
14. Chronic Stress Exacerbates the Immunosuppressive Microenvironment and Progression of Gliomas by Reducing Secretion of CCL3.
Wang X; Zhang L; Zhou Y; Wang Y; Wang X; Zhang Y; Quan A; Mao Y; Zhang Y; Qi J; Ren Z; Gu L; Yu R; Zhou X
Cancer Immunol Res; 2024 May; 12(5):516-529. PubMed ID: 38437646
[TBL] [Abstract] [Full Text] [Related]
15. A Biodegradable Nanosuspension Locally Used for Inhibiting Postoperative Recurrence and brain Metastasis of Breast cancer.
Qian M; Jiang G; Guo W; Huang R
Nano Lett; 2024 Mar; 24(10):3165-3175. PubMed ID: 38426438
[TBL] [Abstract] [Full Text] [Related]
16. A case of dMMR/MSI-H/TMB-H colon cancer with brain metastasis treated with pd-1 monoclonal antibody.
Xiang T; Zhang H; Fang W; Chen W
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2024 Feb; 53(1):58-63. PubMed ID: 38413220
[TBL] [Abstract] [Full Text] [Related]
17. An adult with recurrent atypical teratoid rhabdoid tumor of the spine.
Charles AJ; Smith VL; Goodwin CR; Johnson MO
CNS Oncol; 2024 Jan; 13(1):CNS105. PubMed ID: 38380555
[TBL] [Abstract] [Full Text] [Related]
18. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal cancer: A Preliminary Report of Case Series.
Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H
Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy of pd-1/PD-L1 immunotherapy on brain metastatic non-small-cell lung cancer and treatment-related adverse events: A systematic review.
Phillips W; Thornton Z; Andrews L; Daly R; Higgins J; Davies P; Kurian K
Crit Rev Oncol Hematol; 2024 Apr; 196():104288. PubMed ID: 38331301
[TBL] [Abstract] [Full Text] [Related]
20. The treatment of advanced melanoma: Current approaches and new challenges.
Boutros A; Croce E; Ferrari M; Gili R; Massaro G; Marconcini R; Arecco L; Tanda ET; Spagnolo F
Crit Rev Oncol Hematol; 2024 Apr; 196():104276. PubMed ID: 38295889
[TBL] [Abstract] [Full Text] [Related]
[Next]
